Treatment of Colon Cancer
Significant advances have been made in the study of colorectal cancer over the last few years. A more thorough understanding of the molecular basis of this disease, coupled with the development of new therapeutic approaches, has dramatically altered the way in which patients are managed. Globally nearly 800,000 new colorectal cancer cases are believed to occur each year, which account for approximately 10% of all incident cancers. The incidence rates of Colon Cancer in India in eight population registries vary from 3.7 to 0.7/100,000 among men and 3 to 0.4/100,000 among women. Age impacts colorectal cancer incidence more than any other demographic factor. The incidence of sporadic colorectal cancer increases dramatically above the age of 45 or 50 years of all groups. Symptoms associated with Colorectal Cancer include lower gastrointestinal bleeding, change in the bowel habits, abdominal pain, weight loss, change in appetite and weakness; obstructive symptoms in particular are alarming.
Dendritic cells (DCs) are highly effective antigen presenting cells (APCs) that have become popular in the field of cancer immunotherapeutics. Dendritic cells (DCs), presently known to be the most potent antigen presenting cells, are recently used in adjuvant cancer therapy to stimulate the innate immunity and induce an immune response against specific antigens expressed on tumour cells. Our institiution has successfully completed trials on dendritic cell based immunotherapy for highly advanced colon cancer patients.